Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

A special focus issue on the materials of Prion 2011 meeting in Montreal, Canada.

Cashman NR, Chernoff YO.

Prion. 2012 Apr-Jun;6(2):95-6. doi: 10.4161/pri.20455. No abstract available.

PMID:
22634715
2.

A special focus issue on the materials of PRION 2013 meeting in Banff, Alberta Canada.

Keough K, Cashman N.

Prion. 2014 Jan-Feb;8(1):1. No abstract available.

PMID:
25077317
3.

Prionet Canada: a network of centres of excellence for research into prions and prion diseases.

Wong M, Toth J, Haney S, Tyshenko MG, Darshan S, Krewski D, Leighton FA, Westaway D, Moore SS, Ricketts M, Cashman N.

J Toxicol Environ Health A. 2009;72(17-18):1000-7. doi: 10.1080/15287390903084108.

PMID:
19697232
4.

Prions.

Shkundina IS, Ter-Avanesyan MD.

Biochemistry (Mosc). 2007 Dec;72(13):1519-36. Review.

5.

Molecular Biology of Prion Diseases. Proceedings of a Royal Society discussion meeting. 22-23 September 1993.

[No authors listed]

Philos Trans R Soc Lond B Biol Sci. 1994 Mar 29;343(1306):353-463. No abstract available.

PMID:
7913752
6.

Prions and manganese: A maddening beast.

Brown DR.

Metallomics. 2011 Mar;3(3):229-38. doi: 10.1039/c0mt00047g. Epub 2010 Oct 29. Review.

PMID:
21390367
7.

Hypothesis: the meeting place model for prion disease.

Norris V, Cellier D, Caston J, Valleton JM, Sweetman G, Monnier C.

C R Acad Sci III. 1997 May;320(5):393-8.

PMID:
9239325
8.

[Significance of prion protein in transmission of prions and in pathogenesis of spongiform encephalopathies].

Raeber AJ, Klein MA, Frigg R, Brandner S, Blättler T, Aguzzi A.

Wien Med Wochenschr. 1998;148(4):74-7. Review. German.

PMID:
9611346
9.

Interspecies transmission of prions.

Afanasieva EG, Kushnirov VV, Ter-Avanesyan MD.

Biochemistry (Mosc). 2011 Dec;76(13):1375-84. doi: 10.1134/S0006297911130013. Review.

10.

Prions: health scare and biological challenge.

Aguzzi A, Montrasio F, Kaeser PS.

Nat Rev Mol Cell Biol. 2001 Feb;2(2):118-26. Review.

PMID:
11252953
11.

Cells and prions: a license to replicate.

Nuvolone M, Aguzzi A, Heikenwalder M.

FEBS Lett. 2009 Aug 20;583(16):2674-84. doi: 10.1016/j.febslet.2009.06.014. Epub 2009 Jun 13. Review.

12.

Prion protein transgenes and the neuropathology in prion diseases.

DeArmond SJ, Prusiner SB.

Brain Pathol. 1995 Jan;5(1):77-89. Review.

PMID:
7767493
13.

[Yeast prions, mammalian amyloidoses, and the problem of proteomic networks].

Galkin AP, Mironova LN, Zhuravleva GA, Inge-Vechtomov SG.

Genetika. 2006 Nov;42(11):1558-70. Review. Russian.

PMID:
17163073
14.

Preface. Prion research in perspective III.

Cashman N, Darshan S, Krewski D, Tyshenko MG.

J Toxicol Environ Health A. 2011;74(22-24):1431-2. doi: 10.1080/15287394.2011.618966. No abstract available.

PMID:
22043905
15.

London meeting explores the ins and outs of prions.

Kingman S.

Science. 1993 Oct 8;262(5131):180-1. No abstract available.

PMID:
8105534
16.

Reconstructing prions: fibril assembly from simple yeast to complex mammals.

Sigurdson C, Polymenidou M, Aguzzi A.

Neurodegener Dis. 2005;2(1):1-5. Review.

17.

Prions and prion diseases: fundamentals and mechanistic details.

Ryou C.

J Microbiol Biotechnol. 2007 Jul;17(7):1059-70. Review.

18.

The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity.

Lim YB, Mays CE, Kim Y, Titlow WB, Ryou C.

Biomaterials. 2010 Mar;31(8):2025-33. doi: 10.1016/j.biomaterials.2009.11.085.

PMID:
20022103
19.

Prions, prion diseases and decontamination.

Jung MJ, Pistolesi D, Panà A.

Ig Sanita Pubbl. 2003 Sep-Oct;59(5):331-44. Review.

PMID:
14981553
20.

Fundamentals of prions and their inactivation (review).

Sakudo A, Ano Y, Onodera T, Nitta K, Shintani H, Ikuta K, Tanaka Y.

Int J Mol Med. 2011 Apr;27(4):483-9. doi: 10.3892/ijmm.2011.605. Epub 2011 Jan 25. Review.

PMID:
21271212

Supplemental Content

Support Center